about
No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapyFOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.Role of MGMT as biomarker in colorectal cancer.Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.Role of BAX for outcome prediction in gastrointestinal malignancies.Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons.Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.Inter-observer agreement in GTV delineation of bone metastases on CT and impact of MR imaging: A multicenter study.Bronchiolitis obliterans organizing pneumonia after stereotactic ablative radiation therapy for lung cancer: A case report.Cone-beam CT-based inter-fraction localization errors for tumors in the pelvic region.Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse.Nutritional Intervention for Nonsurgical Head and Neck Cancer Patients Treated with Radiation Therapy: Results from a Prospective Stepped-Wedge Clinical ProtocolLate toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionationRe-irradiation for isolated local recurrence of prostate cancer: MONO-INSTITUTIONAL series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastasesStereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastasesMixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacyCorrection to: Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionationIntra- and inter-observer variability in breast tumour bed contouring and the controversial role of surgical clipsDirect health-care cost of head and neck cancers: a population-based study in north-eastern ItalyPrognostic significance of neutrophil-to-lymphocyte ratio in HPV status era for oropharyngeal cancerMetastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter studyImpact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancerBeyond MicroRNAs: Emerging Role of Other Non-Coding RNAs in HPV-Driven Cancers
P50
Q31083823-3B25316D-28B2-4570-BCB9-55B4662DC222Q34005136-F919EDE9-267C-45F3-9792-E6887EA4F52BQ34706115-76790468-1A32-42C2-A033-96105ADD1FF5Q36341166-01B46B94-8473-4D89-9BAE-0B58DABD37F2Q37548830-201F4D64-B2A5-427B-B384-A07F89A4D8F5Q38108758-CBA5B8F4-E69A-4BDB-B913-0E2DA99D4D20Q38620697-54C94592-218E-4622-89AF-67F2DA484CC6Q40341215-E583FB16-12D4-4588-ABFF-377DA19659D0Q44970937-0BA8323A-3E44-4FD6-A291-3C2BB2C23218Q50054036-969C17E7-95A1-4EDC-9B62-D5E0D5D49382Q50207731-9509071D-F6BA-46BA-A40F-80D7CAFC51E9Q52666088-B7AE17E3-90F1-41A1-ADFF-8F108B39E4D8Q54388409-1E383CF2-9713-4E32-8E88-2E12731A51E5Q57060690-21925A10-390F-423F-8759-270C7EC6D4CEQ57981842-DD981376-A46B-45F2-A416-A9B426313D3CQ58086914-24D9BCE8-3F31-4BED-BE1A-6CA3AED9FBF5Q58199973-12244E65-2000-497C-963B-409F85E0321FQ88404564-A7075F4D-E960-456F-A0AC-667C55B567D7Q89852237-DB7EDFE2-5331-4A5E-8AA4-F2D3CF5C7DA5Q90577547-9082E8BB-DBF9-44C9-B721-75248553C074Q91628333-82E07AEE-43B1-4765-B403-101E678E4E43Q91993252-C8CD68BE-F478-435B-9D6D-6BB5E83ADC6FQ92116078-29954992-0611-41D7-BD85-7E848A7985E7Q92287924-AFE6D236-EC6C-44EF-A2B1-CA4D48F82E7BQ93358193-1EE61B98-26F5-41B2-92BA-80711D23A300Q95320385-6DCEE187-D2FB-48D9-A1E5-7644FDDAF31E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Fanetti
@ast
Giuseppe Fanetti
@en
Giuseppe Fanetti
@es
Giuseppe Fanetti
@nl
Giuseppe Fanetti
@sl
type
label
Giuseppe Fanetti
@ast
Giuseppe Fanetti
@en
Giuseppe Fanetti
@es
Giuseppe Fanetti
@nl
Giuseppe Fanetti
@sl
prefLabel
Giuseppe Fanetti
@ast
Giuseppe Fanetti
@en
Giuseppe Fanetti
@es
Giuseppe Fanetti
@nl
Giuseppe Fanetti
@sl
P106
P21
P31
P496
0000-0002-9677-3176